drugset / Trial / NCT00770744

Efficacy of Lu 31-130 in Patients With Schizophrenia

NCT00770744

Phase 2 Completed 93 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.

Timeline

Start
2008-09
Primary completion
2009-10
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 10 mg Oral
Comparator Olanzapine Small molecule 15 mg Oral
Subject Zicronapine Small molecule 5 mg Oral
Subject Zicronapine Small molecule 7 mg Oral

Indications